fashion -WSS

fashion

author：explore 2025-09-04 22:01:22 - browse：4

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Pfizer is about to make a big push in cancer. Will investors listen?

focus

hotspot

WSS

Color Health wants to make cancer screenings convenient

What will Novo Nordisk's VC do with its influx of cash?

Readout Newsletter: Beam, Prozac, "TechBio" and more

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Pfizer is about to make a big push in cancer. Will investors listen?

Will an HIV vaccine ever be a reality?

explore

fashion

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

RSV injection headlines need to be accurate for good uptake

Moonlake's readout produced a cash windfall. Risks remain

Pfizer is about to make a big push in cancer. Will investors listen?

Psychedelics group wrestles with new pharma identity

The stability of $0 premiums in Medicare Advantage

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

RSV injection headlines need to be accurate for good uptake

What does generative AI mean for health care? We asked experts

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

hotspot

Redefining sustainability for the pharmaceutical industry

CDC picks Alphabet's Verily for wasterwater surveillance contract

Medicare innovation center doesn’t save money, experts say

NEJM study measures Covid brain fog, impact on IQ

Change Healthcare cyberattack shows risk of industry consolidation

'Vaccine

leisure time

focus

hotspot

hotspot